DexCom IPO Assists Firm In Quest For Next-Generation CGMS Approval

DexCom will use part of the $54.9 mil. in net proceeds it expects to garner from an April 14 initial public offering to support ongoing clinical trials for its two continuous blood glucose monitoring systems